Samuel Lentz to Adult
This is a "connection" page, showing publications Samuel Lentz has written about Adult.
Connection Strength
0.172
-
Herzog TJ, Sill MW, Walker JL, O'Malley D, Shahin M, DeGeest K, Weiner SA, Mutch D, DeBernardo RL, Lentz SS. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011 Mar; 120(3):454-8.
Score: 0.040
-
Lentz SS. Transvaginal repair of the posthysterectomy vesicovaginal fistula using a peritoneal flap: the gold standard. J Reprod Med. 2005 Jan; 50(1):41-4.
Score: 0.026
-
Sunwook K, Nussbaum MA, Quandt SA, Laurienti PJ, Arcury TA. Effects of Lifetime Occupational Pesticide Exposure on Postural Control Among Farmworkers and Non-Farmworkers. J Occup Environ Med. 2016 Feb; 58(2):133-9.
Score: 0.014
-
Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
Score: 0.013
-
Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul; 122(1):111-5.
Score: 0.010
-
Parson EN, Lentz S, Russell G, Shen P, Levine EA, Stewart JH. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011 Oct; 202(4):481-6.
Score: 0.010
-
Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010 Jan; 20(1):61-9.
Score: 0.009
-
Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar; 96(3):630-4.
Score: 0.007
-
Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol. 2004 Dec; 95(3):496-9.
Score: 0.007
-
Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol. 2003 Dec 01; 21(23):4350-5.
Score: 0.006
-
Miller DS, Blessing JA, Lentz SS, McMeekin DS. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer. 2003 Oct 15; 98(8):1664-9.
Score: 0.006
-
Thigpen JT, Blessing JA, Olt G, Lentz SS, Bell J. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Sep; 90(3):581-6.
Score: 0.006
-
Hoffman MA, Blessing JA, Lentz SS. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Apr; 89(1):95-8.
Score: 0.006
-
Miller DS, Blessing JA, Lentz SS, Waggoner SE. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2002 Dec; 87(3):247-51.
Score: 0.006
-
Plaxe SC, Blessing JA, Olt G, Husseinzadah N, Lentz SS, DeGeest K, Valea FA. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Chemother Pharmacol. 2002 Aug; 50(2):151-4.
Score: 0.006